RxDoctor Payments Data

Brandy Rose

Psychiatric/Mental Health · Nashville, TNNPI 1669051751

Payments from drug & device makers

$2,971in general payments, 2019–2025

Across 130 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$654
  • Alkermes, Inc.$466
  • Vanda Pharmaceuticals Inc.$352
  • Johnson & Johnson$279
  • Otsuka America Pharmaceutical, Inc.$274
  • Convatec Inc.$150
  • plus $795 from 13 others

What the payments were for

  • Food & beverage$2,969100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,971 in reported general payments places this provider in the 80th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$8,312
Medicare patients
26
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl52$77,748
Invega SustennaPaliperidone Palmitate13$33,822
Paliperidone ErPaliperidone19$8,802
Divalproex Sodium ErDivalproex Sodium87$5,058
Aripiprazole52$3,285
Olanzapine104$3,027
Oxcarbazepine57$2,432
Clozapine25$2,360
Buspirone Hcl131$2,306
Haloperidol86$1,900
Trazodone Hcl185$1,715
Haloperidol Decanoate41$1,712
Benztropine Mesylate127$1,490
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$1,300
Quetiapine Fumarate61$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$100$77,74852 claims
Johnson & JohnsonInvega Sustenna$279$33,82213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →